Sai Parenterals’ Australian subsidiary -- Noumed Pharmaceuticals has successfully renewed its long-term exclusive OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains with an expanded product portfolio, a longer agreement tenure, and a significantly higher agreement value - reflecting a trusted customer relationship. The renewed agreement is valued at 202 million Australian dollar (around Rs 1300 crore) for the term - translating to about 27 million Australian dollar per annum - to be executed over an extended term of seven and half years - with a further 3-year extension option upon mutual consent.
The agreement is also structured for continuous growth: it targets the addition of 12 new products every year, steadily increasing the contract's value and scope every year over its life. Effective July 1, 2026, the renewal cements Noumed's position as a preferred, trusted strategic supply partner to Australia's largest pharmacy networks, and materially strengthens the company’s international business footprint.
Sai Parenterals, along with its subsidiaries, carries out contract research and manufacturing activities for customers engaged in pharmaceutical industries.
